ArticleKidney3602026
Drug-Induced Thrombotic Microangiopathy in Patients with Cancer : A Clinicopathologic Series.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
key pointsGemcitabine, bevacizumab, and doxorubicin were the most common drugs implicated in drug-induced thrombotic microangiopathy in cancer. Cessation of the offending drug was the mainstay of management. The median overall survival was 2.1 years, and the median kidney failure‑free survival was 1.8 years after biopsy-confirmed diagnosis.
backgroundDrug-induced thrombotic microangiopathy (TMA) is a major sequela of cancer therapies. The diagnosis of drug-induced TMA is often presumptive, making accurate clinical characterization difficult.
methodsWe retrospectively reviewed clinical presentation and outcomes of 53 patients with biopsy-proven renal TMA due to cancer therapies in a cancer center between 2001 and 2023.
resultsMedian age at presentation was 64 (44-81) years, and our cohort was 72% (38/53) female. Most common malignancies treated were pancreatic (19%), breast (17%), ovarian (15%), and lung (15%) cancers. Forty-one patients (77%) presented with AKI, of which nine patients (17%) required dialysis. Most common implicated drugs were gemcitabine (51%); bevacizumab (25%); doxorubicin (15%); and various tyrosine kinase inhibitors (19%), including EGF receptor blocker erlotinib (4%). Cessation of the offending drug was the mainstay of management in 51 patients (96%); other treatment strategies included steroids (15%) and eculizumab (8%). After a median follow-up of 4 years (1.1-7.1), median overall survival was 2.1 years and median kidney failure‑free survival was 1.8 years. Among patients with AKI, 16 patients (39%) had kidney recovery within a year. One of nine patients requiring dialysis was weaned off within a year. Older age, lower GFR at presentation, and thrombocytopenia were associated with worse kidney prognosis. Chronic TMA was noted upon kidney biopsy in most of the patients (85%). Pathologic findings associated with worse kidney outcome were the presence of microvascular thrombi and endothelial swelling.
conclusionsAlthough limited by its retrospective nature, our study suggests that doxorubicin and erlotinib are underrecognized causes of drug-induced TMA. Many patients' biopsies had chronic changes in glomeruli, arterioles, and small arteries, indicating that mild, ongoing endothelial injury is present before the development of overt TMA. Clinical vigilance with early cessation of the offending drug may help kidney recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.